REMOVAB

This brand name is authorized in Estonia, Lithuania.

Active ingredients

The drug REMOVAB contains one active pharmaceutical ingredient (API):

1	Catumaxomab UNII M2HPV837HO - CATUMAXOMAB
	Catumaxomab is a trifunctional rat-mouse hybrid monoclonal antibody that is specifically directed against the epithelial cell adhesion molecule (EpCAM) and the CD3 antigen. The EpCAM antigen is expressed on most cancers especially carcinomas. CD3 is expressed on mature T-cells as a component of the T-cell receptor. A third functional binding site in the Fc-region of catumaxomab enables interaction with accessory immune cells via Fc-gamma receptors.
	Read more about Catumaxomab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REMOVAB Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX03	Catumaxomab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1413908, 1413919
LT	Valstybinė vaistų kontrolės tarnyba	1037230, 1037231